{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"limitationsAndCaveats":{"description":"This study also incorporates a China tail, comprising additional patients randomized after the end of the global cohort recruitment. Efficacy and safety of patients randomized in China will be reported at a later date once this separate analysis has been completed."},"pointOfContact":{"email":"information.center@astrazeneca.com","organization":"AstraZeneca","phone":"1-877-240-9479","title":"Global Clinical Lead"}}